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Abstract
Background: Health care providers aim to stimulate self-management in type 2 diabetes (T2DM) patients. However,
they have a limited number of patient contacts to do this. With the growing number of T2DM patients, innovative
and cost-effective interventions to promote self-management are needed. We aim to evaluate the effectiveness of
diabetes self-management education via a smartphone app in T2DM patients on insulin therapy.
Methods: Non-blinded two-arm multi-centre randomised controlled superiority trial with parallel-groups and equal
randomisation (‘TRIGGER study’). Eligible patients are 40–70 years, on insulin therapy since at least 3 months, with
HbA1c > 53 mmol/mol (> 7%). In total 228 patients will be recruited. The intervention group (n = 114) will receive
diabetes self-management education via a smartphone app to trigger diabetes self-management: unidirectional text
messages, free of charge, evidence and psychological theory based, with regard to dietary habits, physical activity,
hypoglycaemia and glucose variability. Patients choose their preferred frequency (two to six times per week), topics
(two or three additionally to hypoglycaemia, which is an obligatory topic), and duration (6 or 9 months). The control
group (n = 114) will receive care-as-usual. The primary study endpoint is the HbA1c level after a follow-up of 6 months.
The percentage of patients who achieve an HbA1c level ≤ 53 mmol/mol (≤7%) without hypoglycaemia (plasma
glucose < 3.5 mmol/L (< 63 mg/dL)) is a co-primary outcome. Secondary outcomes are body mass index, waist
circumference, insulin dose, lipid profile, blood pressure, number of hypoglycaemic events, glycaemic variability,
self-management (SDSCA), food habits (FFQ), physical activity (IPAQ), health status (EQ-5D-5 L, SF36), diabetes-
dependent quality of life (ADDQoL), diabetes treatment satisfaction (DTSQ), satisfaction with the app, the cost-
effectiveness of the intervention after 3 months, and sustainability of the intervention effect (3 months extra follow-up
in intervention group to compare prolonged to discontinued use of the app). We will use the intention-to-treat
principle to analyse data.
Discussion: Innovative solutions are needed to improve the (cost-) effectiveness of self-management for the increasing
number of T2DM patients. This trial will provide evidence on the effectiveness of a newly developed smartphone app,
designed to trigger diabetes self-management.
Trial registration: Dutch Trial Register NTR5515, registration date: 18 November 2015 (prospectively registered).
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Background
Self-management forms a crucial part of type 2 diabetes
(T2DM) treatment, especially for insulin treated individ-
uals. It includes healthy food choices, frequent exercising,
regular blood glucose monitoring, and dietary and insulin
dose adjustments related to physical activity. These adap-
tations are necessary to achieve optimal glycaemic control
(without much variability and hypoglycaemia) and weight
loss, and to prevent both microvascular and macrovascu-
lar complications. However, for most patients, diabetes
self-management is challenging and difficult to maintain.
Besides, results of self-management interventions are
often effective in the short-term, but have mixed
long-term results [1]. Health care providers aim to stimu-
late self-management, but due to the limited number of
diabetes monitoring visits they are in the position to trig-
ger diabetes self-management only a few times a year [2].
Moreover, with the growing number of T2DM patients
and the expected shortage of health care providers in
some countries, innovative and (cost-) effective solutions
to promote self-management are needed.
A potential low-cost intervention to stimulate diabetes
self-management may be the use of a smartphone app.
The number of diabetes apps has tremendously in-
creased during the past years. In the iTunes store alone,
there was a ten-fold increase from 60 in 2009 [3], to 622
in 2013 [4]. When the number of diabetes apps from
Google Play, BlackBerry, Windows and Ovi Store are
added to that number, the total number of diabetes apps
already exceeded 1800 in 2013 [4]. Unfortunately, many
of these diabetes apps have not been studied in medical
research, i.e. they are not evidence based. In one study,
only 16 out of the 87 identified apps could be found in
medical literature; 71 apps were solely found in the
iTunes Store [5].
A common feature of a diabetes app is self-monitoring
of blood glucose levels, blood pressure, physical activity,
weight, medication intake and food intake [3, 5–7]. For
blood glucose, blood pressure and physical activity (step
counter), automatic data entry is often possible, but apps
facilitating these features are likely to be associated with
higher costs. Another common feature is interactive
communication with health care providers [3, 7]. Many
of the apps that have been investigated showed to be
effective [6–8]: HbA1c decreased [7, 9, 10] and self-man-
agement improved [11]. However, for most patients,
daily entry of personal data is a tedious task [6], often
resulting in infrequent or non-use of the app [11]. Be-
sides, technologies for automatic data transfer are more
expensive, as is true for interactive communication and
tailored feedback from health care providers [12].
Another type of a smartphone app, that may have a more
sustainable effect on self-management, is an educational
app that sends automated app-messages that function as
behavioural triggers; it requires less effort from both
health care providers and patients, and may be a low-cost
solution compared to the abovementioned strategies. We
hypothesise that receiving cost free behavioural triggers
on preferential topics and with a self-chosen frequency,
sent as app-messages via a smartphone app, will result in
better diabetes self-management and improved glycaemic
control, less weight gain and less glucose variability with
less hypoglycaemic events in T2DM patients on insulin
therapy.
Theoretical framework of the intervention
Behavioural triggers (also known as prompts, stimuli or
cues to action) play a pivotal role in behaviour change
[13]. They play an important role in the ‘Health Belief
Model’ [14], in Leventhal’s self-regulation model [15]
and in the ‘Transtheoretical Model of Behaviour Change’
[16]. In the ‘Fogg Behavior Model’, triggers are even of
paramount importance [13]. In all these theories, behav-
ioural triggers have some overlapping characteristics.
Firstly, a trigger stimulates the individual to engage in
health-promoting behaviour [14, 15]. Secondly, a trigger
can be either internal (i.e. signs and symptoms such as
pain or dyspnoea) or external, emerging in various
forms: from a warning label on a product to a reminder
e-mail from the dentist [14, 15]. Finally, external triggers
can have a motivational element (e.g. a trigger that high-
lights fear), can increase the individuals’ ability to behav-
iour change, or can function as a signal (e.g. a reminder)
[13]. While triggers are import for behavioural change,
for a given behaviour to occur more than a single trigger
is needed, namely a certain level of perceived health
threat, severity, self-efficacy and a sufficient level of mo-
tivation [13–16]. The intensity of the trigger will depend
on the presence and level of for example motivation (i.e.
the less motivated, the more intense the trigger should
be to achieve the intended behaviour) [13, 14]. On the
other hand, receiving a behavioural trigger can be the
last factor to overcome barriers and to adapt the
intended behaviour.
Behavioural triggers can be sent as text messages. Evi-
dence on the effectiveness of unidirectional triggers deliv-
ered by mobile phone technology (either via app or SMS)
so far is mainly based on studies with a small number of
patients and a short duration, focussing on feasibility [8,
17–19]. Moreover, studies were conducted in patient sam-
ples that may not be representative for Western countries,
e.g. in Iraqi patients and in resource-poor patients in the
United States (for a greater part low income groups and
from ethnic minority groups, frequently without health
insurance) [20, 21]. Furthermore, the sustainability of
app-triggers or SMS-triggers on diabetes self-management
is unknown, but important for successful implementation.
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Methods
Research questions
We aim to determine the effectiveness of unidirectional
evidence based app-messages on self-management of in-
sulin treated T2DM patients. This will be determined
via the following research questions (1) What are the ef-
fect of the intervention on HbA1c level and on the per-
centage of patients who achieve an HbA1c level ≤
53 mmol/mol (≤7%) without hypoglycaemia (plasma glu-
cose < 3.5 mmol/L (< 63 mg/dL) after a follow-up period
of 6 months? (2) What are the effects of the intervention
on body mass index (BMI), lipid profile, blood pressure,
waist circumference, prescribed insulin dose, number of
hypoglycaemic events and glucose variability after a
follow-up period of 6 months? (3) What are the effects of
the intervention on self-management activities, food
habits, physical activity, health status, diabetes related
quality of life and diabetes treatment satisfaction after a
follow-up of 6 months? (4) What is the cost-effectiveness
of the app-trigger intervention compared to usual care?
and (5) Is the intervention effect sustainable after 3
months of prolonged versus discontinued use of the app
in the intervention group?
Study design
The TRIGGER study is designed as a non-blinded
two-arm multi-centre randomised controlled superiority
trial with parallel-groups and equal randomisation (1:1).
This study protocol is reported following the SPIRIT
guideline for standard protocol items in interventional
trials [22]. The information on the mHealth intervention
is reported following the mHealth evidence reporting
and assessment (mERA) checklist [23].
Ethics and trial registration
The Medical Research Ethics Committee of the University
Medical Center Utrecht has approved the study protocol
(protocol number: NL53125.041.15, issued October 2015,
issue date amendment: May 2016 (reason: additional re-
cruitment in secondary care)). The trial is registered in the
Dutch trial register (trial-ID: NTR5515). Important proto-
col modifications will be communicated with the Medical
Research Ethics Committee and the trial register.
Setting
The study will be conducted in general practices and hos-
pitals across the Netherlands, starting from December
2015 onwards. In the Netherlands, approximately 85% of
all T2DM patients are treated in primary care. Practice
nurses conduct the regular monitoring visits two to four
times yearly. Once a year, the monitoring visit is con-
ducted by, or together with, the general practitioner (GP),
but when necessary more often. Patients are referred to
hospital based internists/endocrinologists when adequate
glycaemic control cannot be achieved or when other prob-
lems occur that are beyond the scope of the GP. The in-
ternists/endocrinologists closely collaborate with
specialised diabetes nurses [2]. All participating sites can
be found at the trial website [24]. Participating hospitals
are (in alphabetical order): Bethesda Diabetes Research
Center, HagaZiekenhuis, Meander Medical Center, Röpck-
e-Zweers Ziekenhuis and Ziekenhuis Gelderse Vallei.
Participants
Eligible participants are T2DM patients aged 40–70 years,
treated for their diabetes by the recruiting health care pro-
vider, sufficiently fluent in Dutch, on insulin treatment
since at least three months, and with HbA1c > 53 mmol/
mol (> 7%) at most recent measurement. Logistic require-
ments are the possession of an email address and a smart-
phone. In the Netherlands, 96% of the population has
access to a personal computer [25]. In 2016, 89.6% of the
population between 45 and 65 years old had access to a
mobile phone with internet capacity, while among those
above 65 years only 50.9% had access [26]. We used age as
an inclusion criterion because we expect the probability
for patients > 70 years to possess a smartphone to be
lower than in the younger patient group and besides, for
many patients aged > 70 years a less stringent glycaemic
target is recommended according to the Dutch Primary
Care Guidelines [2]. Patients are excluded when they have
a history of alcoholism, drug abuse, dementia or a major
psychiatric disorder that is likely to invalidate informed
consent or limit the ability of the individual to comply
with the protocol requirements.
Recruitment
Most general practices are recruited via diabetes care
groups. These care groups organise and coordinate the
diabetes care programme, and are responsible for the de-
livery of diabetes care [27]. Care groups in the
Netherlands are similar to Accountable Care Organiza-
tions in the USA and Clinical Commission Groups in
the UK [27]. We expect that about 40 general practices
and five small to medium sized hospitals are needed to
enrol the required number of 228 participants (see Fig. 1
and ‘Sample size’ below). When a general practice or a
hospital consents to participate, the researchers will in-
struct the practice nurse or diabetes nurse. Afterwards
the practice nurse, diabetes nurse, GP or hospital data
manager selects the patients based on a query in the
electronic medical record, the practice nurse or the dia-
betes nurse conducts the informed consent procedure
and performs the data collection.
Randomisation
Simple, fixed block randomisation will be generated at the
patient level. Randomisation will be performed centrally
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using a web-based computerised random-number gener-
ator provided by an independent contractor (Research
Online, https://random.mendixcloud.com/login.html) at
the research centre. For general practices, the coordinat-
ing researcher will generate the allocation sequence, in the
order in which patients are enrolled, and forwards this
information to the company that developed the software
for the smartphone app. Ten days after the patient has
provided written informed consent, the practice nurse will
inquire after the randomisation outcome and will inform
the patient about it, and on how to use the paper patient
diary. The patient receives an email with regard to the
steps to be taken to receive the app-messages and on how
to complete the online questionnaires. For the hospitals,
the coordinating researcher will forward the randomisa-
tion outcome directly to the patient 10 days after the
patient has provided written informed consent.
The intervention
Patients randomised to the intervention group will re-
ceive app-messages regarding dietary habits, physical
activity, prevention of hypoglycaemia, and glucose vari-
ability (see Fig. 2). These app messages are clear, unidir-
ectional messages containing specific goals, healthy
living challenges, information, or questions (see Table 1
for examples). They are sent in Dutch only. The con-
tent of the intervention is determined by reviewing
research literature of existing mHealth interventions
and is in accordance with (inter-) national guidelines.
An independent dietician, physiotherapist and practice
nurse reviewed the messages’ content and wording.
Afterwards, two T2DM patients on insulin reviewed
the messages. Feedback was used for finalisation before
the messages were entered into the app software system.
Messages are framed grammatically correct, free of textese
(“SMS language”), benefit-oriented, polite, nonaggressive
and directive [28, 29]. Moreover, the intervention is tai-
lored, according to patient’s preferences (see further). The
intervention is free of charge, which is especially important
for people with low socio-economic status; which might be
a category of patients that needs self-management
support but is not well approached by ‘conventional’
educational sessions [30].
Users will receive a push notification to direct them to
open the app when a new app-trigger is available. When
the app is not opened in the following 24 h, a reminder
SMS is sent: the SMS fall-back system. The number of
reminder SMSs will be monitored.
The timing of the messages is either at random times
between 9.30 a.m. and 8.00 p.m. or at times associated
with the content of the message (e.g. messages contain-
ing advice for dinner are sent in the morning or early
afternoon in order to get the receiver to adapt to that
advice). The intervention will be tailored to the patients’
preferences, they can choose on:
– The topics: hypoglycaemia will be a mandatory
topic, it should be combined with at least two of the
following topics: dietary habits, physical activity or
glucose regulation (including glycaemic variability).
– The frequency: two or six times per week, one app-
trigger per day.
– The option to prolong the intervention with another 3
months after the first 6 months. During this period the
patient will receive app-triggers with unaltered fre-
quency and topics.
In an average 
general practice 
(2350 patients), 
T2DM patients 
are treated (15 T2DM 
patients are treated in 
secondary care)
5
hospitals
10-70% will be on 
insulin therapy
40% aged between 
40 and 70 years and 
baseline HbA1c >53 
mmol/mol (>7%)
228
participants
12,500
T2DM patients
1400 
eligible patients
40
general practices
3500
insulin therapy
Expected response 
rate 20%
Fig. 1 Participant flowchart with the expected number of patients
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Apart from receiving app-triggers, the intervention
group will receive usual care for their T2DM.
Patients randomised to the control group receive
usual care according to the Dutch primary care guide-
lines, that advise two to four diabetes monitoring visits
per year [2]. Through diabetes education from either
the GP or the practice nurse, patients learn about target
values for glycaemic control, lipids and blood pressure,
a healthy lifestyle, recognising hyperglycaemic or
hypoglycaemic episodes and how to respond to these
episodes. Patients randomised to the control group are
not able to use the smartphone app we developed. To
increase the participation rate, patients in the control
group will be given the opportunity to use the app after
the study has ended.
Technical details of the smartphone app
The smartphone app is compatible with Android and
iOS operating systems. A proprietary personal health
record (PHR) platform (“Gezondheidsmeter”, Curavista
eHealth) is combined with both Android and iOS smart-
phone app technology for the end-user. The PHR plat-
form is the host for the push message technology. The
push message technology contains the algorithms for
timely delivery, logging of end-user opening the message
and fall-back SMS. Android and iOS technology is used
to create an app for reception and storage (library) of
the push messages. The mHealth intervention has no
connection or interaction with any national or regional
Health Information System. We did not involve end-
users in usability testing but tested the technical aspects
of the intervention ourselves. The PHR platform is sub-
jected to Dutch privacy laws and has concluded a com-
pliant data processing agreement. The messages do not
contain any personal information. The logging data,
such as successful delivery of messages, are anonymised
by separating them from the personal data.
Outcomes
The primary study outcome is glycaemic control, defined
as the HbA1c level after a follow-up of 6 months in the
app-trigger group compared to the control group. As a
co-primary outcome we will analyse the percentage of
Fig. 2 TRIGGER app home screen. Translation: contact onderzoekers
= contact information; informatie studie = study information;
instellingen = settings; voeding = nutrition; beweging = physical
activity; hypo’s voorkomen = preventing hypoglycaemia; glucose
regulatie = glucose regulation
Table 1 Examples or app messages
Category Message
Dietary habits - Fruit juices are not as healthy as many people think:
they contain lots of sugar and calories. Try to
consume fruit juices as infrequently as possible, eat
fruit instead!
- Don’t drink any soda today. Choose water, or tea or
coffee without any sugar instead.
Physical activity - Take the stairs instead of the elevator, wherever you
are. Or take the elevator to one floor below and take
the last stairs. All steps count!
- People with a healthy weight are advised to be
physically active for at least 30 min a day. People
who are overweight are advised to have at least
60 min of physical activity each day.
Prevention of
Hypoglycaemia
- Instruct your spouse, family, neighbour, colleague or
a friend on how they should act when you have a
hypoglycaemic event.
- Do you have nocturnal hypoglycaemic events? Ask
your doctor whether it is advisable to adjust your
insulin dose.
Glucose
variability
- Never inject insulin into the tough skin of insulin-
induced lumps; because of slower absorption there,
this may lead to blood glucose fluctuations.
- When you have high blood glucose levels, it is
important to drink a lot (1.5–2 l sugar free beverages
per day) and to take your medication properly.
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patients who achieve an HbA1c level ≤ 53 mmol/mol
(≤7%) without any hypoglycaemic event (plasma glucose
< 3.5 mmol/L (< 63 mg/dL)). Secondary outcomes are
BMI, body weight, waist circumference, insulin dose, lipid
profile, blood pressure, number of hypoglycaemic events,
glycaemic variability, self-management, food habits, phys-
ical activity, health status, diabetes-dependent quality of
life, diabetes treatment satisfaction and satisfaction with
the app (intervention group only) after 6 months. More-
over, we will investigate the cost-effectiveness of the inter-
vention after 6 months, and the sustainability of the
intervention effect. The latter is investigated in the inter-
vention group only: we will compare the effect of 3
months prolonged use of the app to stopping with the use
of the app, on HbA1c, on the percentage of patients who
achieve an HbA1c level ≤ 53 mmol/mol (≤7%) without any
hypoglycaemic event, BMI, and health status. Prolonged
users are individuals from the intervention group who
choose to continue the intervention after 6 months (T6);
discontinued users are those who do not continue using
the app after T6.
Measurements
At baseline patients will complete seven questionnaires,
regarding self-management activities, food habits, physical
activity, health status, quality of life, diabetes dependent
quality of life and diabetes treatment satisfaction. For a de-
tailed description of the questionnaires see Table 2. Pa-
tients are asked to complete the baseline questionnaires
before randomisation. After 3 months (T3) patients will
complete two questionnaires; after 6 months (T6) patients
will complete eight (control group) to nine (intervention
group: extra questionnaire on satisfaction with the app)
questionnaires (see Table 2). Patients in the intervention
group also complete one questionnaire after 9 months of
follow-up (T9) (see Table 2). All clinical variables are ob-
tained by an online case report form (eCRF) completed by
the practice nurse or diabetes nurse at T0, T6 and for the
intervention group also at T9. In addition to anthropo-
metric (length, weight, waist circumference and blood
pressure) and laboratory parameters (HbA1c and lipid
profile), the following demographic and clinical variables
are collected: age, duration of diabetes, ethnicity, level of
education, smoking status (current, former, never), pres-
ence of microvascular complications (nephropathy, retin-
opathy, neuropathy) and macrovascular complications
(cardiovascular diseases), and diabetes medication use (in-
cluding insulin injection frequency and dose).
For the cost-effectiveness analysis, data on health care
use are extracted from both the electronic medical rec-
ord and from the questionnaires sent to the participants
at T3 and T6. The number of hypoglycaemic events and
the glycaemic variability are extracted at T6 (control
group and intervention group) and at T9 (intervention
group) from patient diaries, handed out to the patients at
the start of the study. These diaries are designed for the
purpose of this study only: patients record information on
all hypoglycaemic events during the study, and once a
week blood glucose values throughout the day (fasting
plasma glucose and three pre-prandial values). For an
overview of the study design and procedures: see Fig. 3.
Monitoring, safety and confidentiality
A monitor will assess the safety and validity of the re-
search data. Due to the low risk character of the inter-
vention, only spontaneously reported adverse events will
be reported in the result paper. Research data will be
stored in code: all participants will receive their own ser-
ial number based on the study site and the eCRF num-
ber. Clinical data of the participants will be extracted
from electronic medical records and anonymously pro-
vided on an eCRF to the coordinating research center.
Concealment of allocation and blinding
The study is not blinded at patient level because of the
nature of the intervention, which requires overt partici-
pation. The practice nurses/diabetes nurses/outcome as-
sessors are also not blinded to patient allocation.
Sample size
Based on the decrease in HbA1c in previous mHealth
studies [9, 10, 18, 21, 31], we expect a mean difference in
HbA1c level of 0.41% with a standard deviation of 1.1%
between the intervention group and the control group
after 6 months. To detect this difference in the primary
outcome with an 80% power and a non-significant differ-
ence of 5% after 6 months, 228 T2DM patients (114 per
treatment group) are needed. We used SAS version 9.4
(SAS Corp., Cary NC) for the sample size calculation.
Analysis
Age and sex of our study population will be compared
to those who declined to participate to investigate selec-
tion (bias). We will also compare baseline characteristics
of our study population to those of similar Dutch T2DM
patient cohorts.
Intention-to-treat analysis will be performed for the
primary and secondary outcomes. If necessary, a mul-
tiple imputation technique will be used to handle miss-
ing data.
To analyse continuous variables we will use general
linear models. Binary outcome variables will be analysed
with logistic regression. To analyse the number of
hypoglycaemic events we will use a Poisson regression.
If necessary, the analysis will be adjusted for overdisper-
sion or underdispersion.
Firstly, we will perform a univariable analysis to exam-
ine the intervention effect. Afterwards we will perform a
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multivariable analysis corrected for the following base-
line characteristics: baseline value, age, sex, duration of
diabetes and insulin dosage.
Cost-effectiveness analysis
The cost-effectiveness of the intervention will be de-
termined from a healthcare perspective. EQ-5D-5 L
will be used to calculate quality-adjusted life-years
(QALYs), following an area under the curve approach,
with interpolation between measurements. All health
care use will be valued following standard costs per
unit as advocated for use in Dutch health economic
evaluations. Cost differences between intervention and
control groups will be related to QALY differences
Table 2 Description of questionnaires
Questionnaire Description Score range Completed at
Summary of Diabetes
Self-Care Activities
Measure (SDSCA) [34]
11 Items assessing several aspects of the diabetes
regimen: diet, exercise, blood glucose testing, foot
care and smoking. Items measure how many days
a patient has performed self-care activities in the
last 7 days.
10 Items rated on an 8-point Likert scale,
measuring how many days an activity is
performed in the last week. One item measures
smoking status (yes/no) and the amount of
cigarettes smoked in the last week. Each of the
domains is measured separately.
T0, T6
Food habits
questionnaire (FFQ) [35]
18 Items assessing patient’s habits with regard to
preparation of food, fatty food intake, dietary
products and fruit and vegetable intake.
All items differ in the scoring ranges, varying from
four scoring options (never, sometimes, frequently
or always) to eight options (never to 7 days a week)
T0, T6
International Physical
Activity Questionnaire
(IPAQ) [36]
25 Items assessing how many days physical
activities are performed during the past 7 days in
four domains (work, transportation, housework
and leisure-time), 2 items assess sedentary
behaviour.
Total physical activity score is calculated as the
sum of the number of minutes of total moderate
activity for each subdomain, plus two times the
number of minutes of total vigorous activity for
each subdomain.
T0, T6
EQ-5D-5 L [37] Quality of life questionnaire.
The classification system (EQ-5D-Profile) covers
mobility, self-care, daily activities, pain/discomfort
and anxiety/depression. The Visual Analogue Scale
(EQ-5D-VAS) is a graduated, vertical line, anchored
at 0 (worst imaginable health state) and 100 (best
imaginable health state).
For the EQ-5D-Profile each domain has five levels
of functioning: from no problems to severe
problems.
For the EQ-5D-VAS the patient is asked to rate
his/her health by marking a point on the EQ-5D-VAS
that best reflects his/her actual health state.
T0, T3, T6, T9a
The Short Form (36)
Health Survey (SF-36) [38, 39]
Generates a profile of scores on eight dimensions
of health status: Physical Functioning (10 items),
Role Physical (4 items), Bodily Pain (2 items),
General Health (6 items), Vitality (4 items), Social
Functioning (2 items), Role-Emotional (3 items)
and Mental Health (5 items).
The different scales can be summarized in two
component scores: the Physical Component Score
and the Mental Component Score. Both scores
range from 0 (least favorable health state) to 100
(most favorable health state).
T0, T6
The Audit of Diabetes-
Dependent Quality of Life
(ADDQoL) [40]
A measure of impact and importance of diabetes
and its treatment on quality of life. The ADDQoL
consists of 19 diabetes-specific items and two
overview items. For each item the patient is asked
how things would be without diabetes, with an
impact rating and an importance rating.
The impact rating ranges from − 3 (very much
better) to 1 (worse), the importance rating ranges
from 3 (very important) to 0 (not at all important).
The average weighted impact ADDQoL score is the
sum of all the weighted impact scores in the
nominator and of the number of domains in the
denominator, and ranges from − 9 to 3.
T0, T6
Diabetes Treatment
Satisfaction Questionnaire
(DTSQ) [41]
Includes 8 items. In question 1 and 4–8 the
satisfaction with the treatment is better if the
scores are higher. In questions 2 and 3, lower
scores indicate blood glucose levels closer to the
ideal, and higher scores indicate problems.
Scores range per item from 6 (very satisfied) to 0
(very dissatisfied); total score range 36 to 0.
T0, T6
Satisfaction and usability of
the app
Questionnaire newly developed by the researchers
contains questions about the satisfaction with
regard to receiving app-triggers, frequency, timing
and comprehensibility, see Additional file 1.
All items will be rated on a 5-point Likert scale. T6a
Outpatient clinic visits and
paramedical health care use
Newly developed questionnaire contains one
question on outpatient clinic visits (for patients
recruited from primary care) or GP visits (for
patients recruited from hospitals) and three
questions on paramedical health care use:
whether patients have visited a dietician, a
physiotherapist or a specialised feet therapist the
past 3 months.
All four questions are answered with yes or no. In
case of a ‘yes’, patients have to fill in how many
times they have visited the physician/therapist.
T3, T6
Abbreviations: T0 baseline measurement, T3 measurement after 3 months of follow-up, T6 measurement after 6 months of follow-up, T9
measurement after 9 months of follow-up
aCompleted by intervention group only
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between groups. A probabilistic sensitivity analysis
will be performed using bootstrapping. Results will be
presented graphically in Cost-effectiveness Acceptabil-
ity Curves.
Discussion
Self-management is crucial for T2DM patients, espe-
cially for those on insulin therapy. However, to be effect-
ive, self-management education should be intensive [32],
and thus will be costly. Moreover, worldwide there is a
rapid increase in the number of T2DM patients. Against
that background, cost-effective solutions to promote dia-
betes self-management are pivotal. If our newly devel-
oped app proves to be cost-effective, it could be used by
all insulin treated T2DM patients because the messages
are evidence-based and not region-specific. The topics
‘dietary habits’ and ‘physical activity’ can also be used to
stimulate diabetes self-management in the non-insulin
users. The app may be a standalone intervention but can
also be used as part of a more comprehensive program.
A possible limitation for delivery at scale might be the
attitude of health care providers towards new technolo-
gies. Whereas the use of automated unidirectional mes-
sages may seem simple, a recently conducted systematic
review and meta-analysis on this topic showed that
one-way and two-way messages had a very similar effect,
while two-way messages are usually more resource in-
tensive [33].
An operational issue that may occur during the study is
that patients stop reading the text messages, while they
T2DM patients
Exclusion criteria
- History of alcohol or 
drug abuse
- Dementia
- Major psychiatric disorders(s) 
that may interfere with
informed consent or protocol 
requirements
Inclusion criteria
- Insulin therapy since at least
3 months
- Most recently measured HbA1c 
>7% (>53 mmol/mol) 
- Age 40-70 years
- Possession of a smartphone
and e-mail address
- Sufficiently fluent in Dutch
Intervention group
receiving app-triggers + 
standard care
Control group receiving
standard care
Start-up visit
- Physical examination
- Blood sample
- Questionnaires
Informed consent
End of study
After 6 months follow-up
- Physical examination
- Blood sample
- Questionnaires
After 6 months follow-up
- Physical examination
- Blood sample
- Questionnaires
After 9 months follow-up
- Weight
- HbA1c
- Questionnaire
Randomisation
Continued use
of the app
Discontinued
use of the app
End of study
After 3 months follow-up
- Questionnaires
After 3 months follow-up
- Questionnaires
Fig. 3 A schematic diagram with an overview of the study design and the main procedures
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are not formally withdrawn from the study. However,
since we are able to monitor the number of reminder
SMSs sent (SMS fall back), we will be able to monitor the
‘adherence’. Moreover, this study is a real-life pragmatic
trial; in real-life we also expect non-use or infrequent use
of a smartphone app. Another issue that may arise, is that
because all patients are informed about the study before
they sign informed consent and before they are rando-
mised, patients in the control group may also get aware of
the existence of diabetes apps. Some patients in the con-
trol group might start using other diabetes apps during
the study. To overcome this, patients in the control group
will not have access to the smartphone app developed for
the purpose of this trial, but will be offered to use it imme-
diately after. Besides, both patients in the intervention and
control group are equally able to use other diabetes apps.
Barriers to the adoption of the intervention among
study participants may play a role. It is possible that this
intervention is less effective among certain subpopula-
tions that may be considered hard to reach (i.e. men,
low socio-economic status and those who do not regu-
larly attend health services). For that reason we will look
at selection bias. This trial will include a relatively high
number of T2DM patients, as suggested by a recent re-
views [8, 19, 33]. It will add to the evidence base for
mHealth interventions to stimulate self-management in
insulin treated T2DM patients. The results may be of
interest for health care providers, patients, patient orga-
nisations and policy makers who aim to increase dia-
betes self-management.
Additional file
Additional file 1: Satisfaction and usability of the app questionnaire.
(DOCX 18 kb)
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